BeiGene

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

BeiGene develops drugs designed to fight cancer using molecular targeting and immuno-oncology technologies.

BeiGene: Oncological Engineering Set To Break Boundaries

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:50 a.m. ET. A live webcast can be accessed from the investors section of BeiGene's website at http://ir.be

BeiGene to Present at the Cowen 42nd Annual Health Care Virtual Conference

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the fourth quarter and full year of 2021, recent business highlights, and anticipated upcoming milestones. “Last year was transformative for our company, and we have built strategic competitive advantages that will help BeiGene to achieve our mission of ma

BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results

BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the European Medicines Agency (EMA) has accepted for review two new indication applications for its BTK inhibitor BRUKINSA® (zanubrutinib) for the treatment of patients with chronic lymphocyti

BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma

CAMBRIDGE, Mass. and BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene announces approval for BRUKINSA (zanubrutinib) by Swissmedic for the treatment of adult patients with Waldenström's Macroglobulinemia

BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström's Macroglobulinemia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)-- #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the Guggenheim Healthcare Talks, 2022 Oncology Conference on Thursday, February 10, 2022 at 9:00 a.m. ET. A live webcast can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available for 90 days following

BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene announces the appointment of Margaret Dugan, M.D., and Alessandro Riva, M.D., to its Board of Directors.

Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces an sNDA for BRUKINSA in first-line chronic lymphocytic leukemia has been accepted in China with breakthrough therapy designation.

BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced positive findings from the global Phase 3 RATIONALE 305 trial of tislelizumab versus placebo in combination with chemotherapy as a first-line treatment for patients with locally advanced, unresectable or metastatic gas

BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer

CAMBRIDGE, Mass., & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces acceptance of a supplemental New Drug Application in China for BRUKINSA in Waldenström's macroglobulinemia based on the ASPEN trial.

BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström's Macroglobulinemia

The stock price of BeiGene (NASDAQ: BGNE), a China-based biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a fall of 15% over the last twenty-one trading days, while it is up 5% over the last week.

Will BeiGene Stock Rebound After A 15% Fall Over The Last Month?

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #JPMconference--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the J.P. Morgan 40th Annual Healthcare Conference on Tuesday, January 11, 2022 at 5:15 p.m. ET. A live webcast can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available for 90 days following the event

BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has approved BeiGene's anti-PD-1 antibody tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell

China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Repligen

Sarepta Therapeutics

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

3 Biotech Stocks Worth Adding to Your Portfolio Next Year

I-Mab

In these troubled times of U.S.-China tensions, sometimes being a copycat has its benefits. The vast majority of the many publicly listed drug makers in China are essentially copycats that license mature drugs from other, mostly western, developers to sell in China.

As U.S. Takes Aim At China Drug Makers, Innovators Appear At Biggest Risk

Novartis

Novartis (NVS) signs collaboration and license agreement with BeiGene for ociperlimab (BGB-A1217), expanding research and development activities in immuno-oncology.

Novartis (NVS) Collaborates With BeiGene for Oncology Drug

BeiGene Ltd (NASDAQ: BGNE) announced an option, collaboration, and license agreement with Novartis AG (NYSE: NVS) to develop, manufacture, and commercialize BeiGene's ociperlimab in North America, Europe, and Japan.  Ociperlimab is currently being investigated in two global Phase 3 trials, the AdvanTIG-301 and AdvanTIG-302 trials, combined with tislelizumab in lung cancer.

Novartis Inks Option Agreement For BeiGene Anti-Cancer Therapy For Over $1 Billion

BeiGene Ltd. BGNE, +0.25% said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG NVS, -0.20% to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China.

BeiGene to receive up to $1 billion in oncology deal with Novartis

Basel, December 20, 2021 — Novartis announced today the signing of an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the company's research and development activities in immuno-oncology. Ociperlimab is a late-stage TIGIT inhibitor, a novel class of anti-cancer therapies that blocks the TIGIT protein receptor. Ociperlimab is currently being evaluated in two Phase III lung cancer trials and additional studies are ongoing in a wide range of solid tumors.

Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab

BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene expands collaboration with Novartis to develop and commercialize its TIGIT inhibitor and market five Novartis oncology medicines in China.

BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene's TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the official launch of the BeiGene Bioisland Innovation Center (BIC), an innovator-centric incubator in Guangzhou, China.

BeiGene Announces Launch of Bioisland Innovation Center

Zai Lab Ltd.

The threat of a forced delisting is weighing heavily on these two Chinese biotech stocks.

Why Shares of BeiGene and Zai Lab Are Tanking Today

Wuxi Biologics Cayman Inc

The declines come after the Financial Times reported that the U.S. Commerce Department on Thursday is expected to place some Chinese companies involved in biotechnology on its entity list, which is designed to limit access to key U.S. exports.

Hong Kong-Listed Chinese Biotech Stocks Slide on U.S. Sanction Fears

BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces authorisation of BRUKINSA (zanubrutinib) for the treatment of adults with Waldenström's macroglobulinemia in Great Britain.

BeiGene Announces Authorisation of BRUKINSA (zanubrutinib) from the United Kingdom's MHRA for the Treatment of Adults with Waldenström's Macroglobulinemia in Great Britain

News for BeiGene Stock (BGNE)